Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
88.6M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
82.4M
-
Shares change
-
-1.91M
-
Total reported value, excl. options
-
$736M
-
Value change
-
-$62.5M
-
Put/Call ratio
-
1.74
-
Number of buys
-
93
-
Number of sells
-
-83
-
Price
-
$8.94
Significant Holders of Travere Therapeutics, Inc. - Common Stock (TVTX) as of Q3 2023
224 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock as of Q3 2023.
Travere Therapeutics, Inc. - Common Stock (TVTX) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.4M shares
of 88.6M outstanding shares and own 92.96% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.63M shares), ARMISTICE CAPITAL, LLC (7.5M shares), Deep Track Capital, LP (7.37M shares), MACQUARIE GROUP LTD (4.67M shares), VANGUARD GROUP INC (4.67M shares), STATE STREET CORP (4.4M shares), MILLENNIUM MANAGEMENT LLC (3.35M shares), VR Adviser, LLC (2.62M shares), MORGAN STANLEY (2.24M shares), and Woodline Partners LP (2.15M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.